Global X China Biotech UCITS ETF logo

Global X China Biotech UCITS ETF (CBIO)

Market Closed
LSE LSE
$
$
- Market Cap
- Div Yield
- Volume
$
Previous Close
Day Range
0 0
Year Range
0 0
Want to track CBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CBIO pays dividends to its shareholders, with the most recent payment made on Jan 12, 2023. The next estimated payment will be in 12 Jan 2023 on Jan 12, 2023 for a total of $0.24.
The last earnings report, released on Oct 24, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Global X China Biotech UCITS ETF has completed 4 stock splits, with the recent split occurring on Jun 16, 2025.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

CBIO Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
No Data
End of interactive chart.

Global X China Biotech UCITS ETF Dividends

Catalyst Biosciences Inc logo
CBIO 25 Sep 2026
Estimated
Other
$0.24 Per Share
Catalyst Biosciences Inc logo
CBIO 13 Jan 2023
Paid
Other
$0.24 Per Share
Catalyst Biosciences Inc logo
CBIO 21 Sep 2022
Paid
Other
$1.43 Per Share
Catalyst Biosciences Inc logo
CBIO 20 Aug 2015
Paid
Other
$59.77 Per Share

Global X China Biotech UCITS ETF Earnings

24 Oct 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS
13 May 2024 Date
-
Cons. EPS
-
EPS
28 Mar 2024 Date
-
Cons. EPS
-
EPS
26 Oct 2023 Date
-
Cons. EPS
-
EPS
Catalyst Biosciences Inc logo
CBIO 25 Sep 2026
Estimated
Other
$0.24 Per Share
Catalyst Biosciences Inc logo
CBIO 13 Jan 2023
Paid
Other
$0.24 Per Share
Catalyst Biosciences Inc logo
CBIO 21 Sep 2022
Paid
Other
$1.43 Per Share
Catalyst Biosciences Inc logo
CBIO 20 Aug 2015
Paid
Other
$59.77 Per Share
24 Oct 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS
13 May 2024 Date
-
Cons. EPS
-
EPS
28 Mar 2024 Date
-
Cons. EPS
-
EPS
26 Oct 2023 Date
-
Cons. EPS
-
EPS

Global X China Biotech UCITS ETF (CBIO) FAQ

What is the stock price today?

The current price is $0.00.

On which exchange is it traded?

Global X China Biotech UCITS ETF is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is CBIO.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Global X China Biotech UCITS ETF ever had a stock split?

Global X China Biotech UCITS ETF had 4 splits and the recent split was on Jun 16, 2025.

Global X China Biotech UCITS ETF Profile

LSE Exchange
US Country

Overview

Crescent Biopharma, Inc. is a forward-looking biotechnology firm with a sharp focus on pioneering the development of innovative precision-engineered molecules. These advanced molecules are specifically designed to target validated biological pathways, offering new avenues for the treatment of patients suffering from solid tumors. Since its incorporation in 2024, Crescent Biopharma has been steadfast in its commitment to leverage cutting-edge science and technology to fill significant gaps in cancer care. Positioned at the forefront of biotechnological research and headquartered in the USA, the company strives to transform the therapeutic landscape for solid tumors, aiming to enhance the effectiveness of treatments and ultimately improve patient outcomes.

Products and Services

Crescent Biopharma, Inc. brings forth a unique portfolio of precision-engineered molecules and services, specifically designed to advance the field of oncology. Each product and service reflects the company's dedication to innovation, precision, and care.

  • Precision-Engineered Molecules for Solid Tumors:
  • At the heart of Crescent Biopharma’s offerings are its precision-engineered molecules that target validated biological pathways in solid tumors. These bespoke molecules are developed through rigorous research and cutting-edge technology, with a focus on improving treatment outcomes and minimizing side effects. Their innovative approach ensures that therapies are not only efficacious but also safer and more tolerable for patients, heralding a new era in oncological care.

  • Targeted Therapy Development:
  • Beyond individual molecules, Crescent Biopharma is dedicated to the development of targeted therapies that address the specific genetic and phenotypic characteristics of solid tumors. This personalized approach to treatment underscores the company's commitment to precision medicine, aiming to match each patient with the most effective therapy based on their unique tumor profile. Through targeted therapy development, Crescent Biopharma seeks to optimize cancer care, ensuring treatments are as effective and efficient as possible.

Contact Information

Address: 611 Gateway Boulevard
Phone: 650 871 0761